CTCs are rare, and analysis of biomarker expression, such as HER2, on CTCs provides markedly less comprehensive assessment of the entire tumor than might a tissue biopsy, where hundreds of cells can be analysed. This evidence concerns the gene ERBB2 and neoplasm.